Abstract
Human paraoxonase1 (hPON1) is a potential therapeutic against the toxicity of organophosphorus (OP) pesticides and chemical warfare nerve agents. We tested whether PON1 gene transfer using adenovirus provides protection against the toxicity of the OP diazoxon. Using an adenovirus construct containing hPON1 gene, we showed elevated levels of recombinant hPON1 in vitro in 293A cells and in vivo in mice. The recombinant enzyme was secreted by 293A cells into culture medium and into the systemic circulation of mice. Western blotting revealed that the virally expressed hPON1 had the expected molecular weight of 45 kDa. Recombinant hPON1 in mice was in complex with mouse high-density lipoprotein (HDL) and migrated more slowly than endogenous hPON1 in the human HDL complex. Mice injected with adenovirus expressed PON1 at 600–3480 U ml–1 on day 5 post-treatment, which is 8–50-fold above endogenous. Six mice expressing hPON1 survived 2LD50 doses of diazoxon. Four of the six mice survived a second dose of diazoxon (for a total of 4LD50) administered 24 h later. In contrast, none of the three mice in the control group survived one 2LD50 dose. These results show that hPON1 in mice functions as a prophylactic and offers significant protection against lethal doses of diazoxon.
Similar content being viewed by others
References
Thiermann H, Szinicz L, Eyer P, Felgenhauer N, Zilker T, Worek F . Lessons to be learnt from organophosphorus pesticide poisoning for the treatment of nerve agent poisoning. Toxicology 2007; 233: 145–154.
Jeyaratnam J . Acute pesticide poisoning: a major global health problem. World Health Stat Q 1990; 43: 139–144.
Rochu D, Chabriere E, Masson P . Human paraoxonase: a promising approach for pre-treatment and therapy of organophosphorus poisoning. Toxicology 2007; 233: 47–59.
Maxwell DM, Brecht KM, Chang FC, Koplovitz I, Shih TM, Sweeney RE . Toxicodynamic modeling of highly toxic organophosphorus compounds. J Mol Neurosci 2006; 30: 129–131.
Brimblecombe RW . Drugs acting on central cholinergic mechanisms and affecting respiration. Pharmacol Ther B 1977; 3: 65–74.
Gray AP . Design and structure-activity relationships of antidotes to organophosphorus anticholinesterase agents. Drug Metab Rev 1984; 15: 557–589.
Dirnhuber P, French MC, Green DM, Leadbeater L, Stratton JA . The protection of primates against soman poisoning by pretreatment with pyridostigmine. J Pharm Pharmacol 1979; 31: 295–299.
Wolfe AD, Rush RS, Doctor BP, Koplovitz I, Jones D . Acetylcholinesterase prophylaxis against organophosphate toxicity. Fundam Appl Toxicol 1987; 9: 266–270.
Doctor BP, Saxena A . Bioscavengers for the protection of humans against organophosphate toxicity. Chem Biol Interact 2005; 157–158: 167–171.
Raveh L, Grunwald J, Marcus D, Papier Y, Cohen E, Ashani Y . Human butyrylcholinesterase as a general prophylactic antidote for nerve agent toxicity. In vitro and in vivo quantitative characterization. Biochem Pharmacol 1993; 45: 2465–2474.
Lenz DE, Maxwell DM, Koplovitz I, Clark CR, Capacio BR, Cerasoli DM et al. Protection against soman or VX poisoning by human butyrylcholinesterase in guinea pigs and cynomolgus monkeys. Chem Biol Interact 2005; 157–158: 205–210.
Cerasoli DM, Griffiths EM, Doctor BP, Saxena A, Fedorko JM, Greig NH et al. In vitro and in vivo characterization of recombinant human butyrylcholinesterase (Protexia) as a potential nerve agent bioscavenger. Chem Biol Interact 2005; 157–158: 363–365.
Huang YJ, Huang Y, Baldassarre H, Wang B, Lazaris A, Leduc M et al. Recombinant human butyrylcholinesterase from milk of transgenic animals to protect against organophosphate poisoning. Proc Natl Acad Sci USA 2007; 104: 13603–13608.
Ashani Y, Pistinner S . Estimation of the upper limit of human butyrylcholinesterase dose required for protection against organophosphates toxicity: a mathematically based toxicokinetic model. Toxicol Sci 2004; 77: 358–367.
Lenz DE, Yeung D, Smith JR, Sweeney RE, Lumley LA, Cerasoli DM . Stoichiometric and catalytic scavengers as protection against nerve agent toxicity: a mini review. Toxicology 2007; 233: 31–39.
Stevens RC, Suzuki SM, Cole TB, Park SS, Richter RJ, Furlong CE . Engineered recombinant human paraoxonase 1 (rHuPON1) purified from Escherichia coli protects against organophosphate poisoning. Proc Natl Acad Sci USA 2008; 105: 12780–12784.
Davies HG, Richter RJ, Keifer M, Broomfield CA, Sowalla J, Furlong CE . The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nat Genet 1996; 14: 334–336.
Clendenning JB, Humbert R, Green ED, Wood C, Traver D, Furlong CE . Structural organization of the human PON1 gene. Genomics 1996; 35: 586–589.
Gan KN, Smolen A, Eckerson HW, La Du BN . Purification of human serum paraoxonase/arylesterase. Evidence for one esterase catalyzing both activities. Drug Metab Dispos 1991; 19: 100–106.
Mackness B, Durrington PN, Mackness MI . Human serum paraoxonase. Gen Pharmacol-Vasc S 1998; 31: 329–336.
Costa LG, McDonald BE, Murphy SD, Omenn GS, Richter RJ, Motulsky AG et al. Serum paraoxonase and its influence on paraoxon and chlorpyrifos-oxon toxicity in rats. Toxicol Appl Pharmacol 1990; 103: 66–76.
Li WF, Furlong CE, Costa LG . Paraoxonase protects against chlorpyrifos toxicity in mice. Toxicol Lett 1995; 76: 219–226.
Li WF, Costa LG, Richter RJ, Hagen T, Shih DM, Tward A et al. Catalytic efficiency determines the in-vivo efficacy of PON1 for detoxifying organophosphorus compounds. Pharmacogenetics 2000; 10: 767–779.
Cowan J, Sinton CM, Varley AW, Wians FH, Haley RW, Munford RS . Gene therapy to prevent organophosphate intoxication. Toxicol Appl Pharmacol 2001; 173: 1–6.
Connelly S, Mech C . Delivery of adenoviral DNA to mouse liver. Methods Mol Biol 2004; 246: 37–52.
Clery-Barraud C, Renault F, Leva J, El Bakdouri N, Masson P, Rochu D . Exploring the structural and functional stabilities of different paraoxonase-1 formulations through electrophoretic mobilities and enzyme activity parameters under hydrostatic pressure. Biochim Biophys Acta 2009; 1794: 680–688.
Kuo CL, La Du BN . Comparison of purified human and rabbit serum paraoxonases. Drug Metab Dispos 1995; 23: 935–944.
Li B, Sedlacek M, Manoharan I, Boopathy R, Duysen EG, Masson P et al. Butyrylcholinesterase, paraoxonase, and albumin esterase, but not carboxylesterase, are present in human plasma. Biochem Pharmacol 2005; 70: 1673–1684.
Mackness B, Quarck R, Verreth W, Mackness M, Holvoet P . Human paraoxonase-1 overexpression inhibits atherosclerosis in a mouse model of metabolic syndrome. Arterioscler Thromb Vasc Biol 2006; 26: 1545–1550.
Guns PJ, Van Assche T, Verreth W, Fransen P, Mackness B, Mackness M et al. Paraoxonase 1 gene transfer lowers vascular oxidative stress and improves vasomotor function in apolipoprotein E-deficient mice with pre-existing atherosclerosis. Br J Pharmacol 2008; 153: 508–516.
Li WF, Costa LG, Furlong CE . Serum paraoxonase status: a major factor in determining resistance to organophosphates. J Toxicol Environ Health 1993; 40: 337–346.
Gaidukov L, Bar D, Yacobson S, Naftali E, Kaufman O, Tabakman R et al. In vivo administration of BL-3050: highly stable engineered PON1-HDL complexes. BMC Clin Pharmacol 2009; 9: 18.
Fu AL, Wang YX, Sun MJ . Naked DNA prevents soman intoxication. Biochem Biophys Res Commun 2005; 328: 901–905.
James RW, Deakin SP . The importance of high-density lipoproteins for paraoxonase-1 secretion, stability, and activity. Free Radic Biol Med 2004; 37: 1986–1994.
Moren X, Deakin S, Liu ML, Taskinen MR, James RW . HDL subfraction distribution of paraoxonase-1 and its relevance to enzyme activity and resistance to oxidative stress. J Lipid Res 2008; 49: 1246–1253.
Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Parmo SL, La Du BN . Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest 1998; 101: 1581–1590.
Chilukuri N, Duysen EG, Parikh K, diTargiani R, Doctor BP, Lockridge O et al. Adenovirus-transduced human butyrylcholinesterase in mouse blood functions as a bioscavenger of chemical warfare nerve agents. Mol Pharmacol 2009; 76: 612–617.
Chilukuri N, Duysen EG, Parikh K, Sun W, Doctor BP, Lockridge O et al. Adenovirus-mediated gene transfer of human butyrylcholinesterase results in persistent high-level transgene expression in vivo. Chem Biol Interact 2008; 175: 327–331.
Furlong CE, Richter RJ, Chapline C, Crabb JW . Purification of rabbit and human serum paraoxonase. Biochemistry 1991; 30: 10133–10140.
Kiortsis DN, Tsouli S, Lourida ES, Xydis V, Argyropoulou MI, Elisaf M et al. Lack of association between carotid intima-media thickness and PAF-acetylhydrolase mass and activity in patients with primary hyperlipidemia. Angiology 2005; 56: 451–458.
Mc DH, Ribeiro LP . Ethylene and propylene glycol in the pre-staining of lipoproteins for electrophoresis. Clin Chim Acta 1959; 4: 458–459.
Acknowledgements
This work was supported by funds from Defense Threat Reduction Agency (DTRA), Department of Defense (Project No. 1.D003_09_WR_C to Dr Chilukuri) and US Army Medical and Materiel Command W81XWH-07-2-0034 (to Dr Oksana Lockridge). We also thank Dr Gregory E Garcia (Division of Biochemistry, WRAIR) for valuable suggestions with the manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
The opinions or assertions contained herein are the private views of the authors and are not to be construed as official or as reflecting the views of the Army or the Department of Defense, USA.
Rights and permissions
About this article
Cite this article
Duysen, E., Parikh, K., Aleti, V. et al. Adenovirus-mediated human paraoxonase1 gene transfer to provide protection against the toxicity of the organophosphorus pesticide toxicant diazoxon. Gene Ther 18, 250–257 (2011). https://doi.org/10.1038/gt.2010.136
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/gt.2010.136
- Springer Nature Limited
Keywords
This article is cited by
-
Organophosphorus poisoning in animals and enzymatic antidotes
Environmental Science and Pollution Research (2021)